NGM Biopharmaceuticals Inc.

17/07/2024 | Press release | Distributed by Public on 17/07/2024 14:23

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.